The FDA has approved PALSONIFY, a novel nonpeptide SST2 agonist, as the first once-daily, oral therapy for acromegaly. The approval was based on data from two Phase 3 trials showing rapid, durable, and consistent biochemical control. Crinetics Pharmaceuticals, the company behind PALSONIFY, is celebrating this milestone, with an investor call scheduled for today at 6:00 pm ET. PALSONIFY is set to launch in the U.S. in early October, offering a new treatment option for adults with acromegaly. The drug demonstrated significant symptom reduction with a good safety profile, and long-term results were presented at a recent conference.

Read more at GlobeNewswire: Crinetics Announces FDA Approval of